Obesity in Focus

BioCentury In Depth

With the first wave of GLP-1 therapies poised to become the biggest blockbusters in biopharma history, the focus turns to what's next in obesity, including combination therapies and new mechanisms to address an improved quality and duration of weight loss and co-morbidities.

Sign up now (free) for access to the featured stories below and put BioCentury to work for you.

Featured Analysis

Complimentary access with registration

ArticleDealsDec 4, 2023

Move into obesity will require deep spending by Roche

After $2.7B takeout of Carmot, bigger investment for Roche will come with development programs, commercial buildup to compete with Novo Nordisk and Lilly

ArticleProduct DevelopmentNov 29, 2023

The future of obesity: a conversation with Mads Thomsen

Former Novo Nordisk CSO discusses what’s next for obesity, and the impact quantum computing may have on life sciences

ArticleProduct DevelopmentAug 10, 2023

Obesity mechanisms in the clinic: which overlap, and which branch out

Like incretins, most clinical programs modulate glucose homeostasis and appetite, but a few work in new ways that could be more selective for fat loss

More Obesity Analysis from BioCentury

Available to BioCentury Subscribers Only